1. COPIKTRA (duvelisib) receives European Union marketing authorization for the treatment of relapsed or refractory CLL and refractory FL. News release. Secura Bio, Inc. June 9, 2021. Accessed June 9, 2021. https://prn.to/3zfFVLV2. COPIKTRA (duvelisib) receives positive CHMP opinion for the treatment of relapsed and refractory CLL and refractory FL. News release. Secura Bio, Inc. April 1, 2021. Accessed June 9, 2021. https://prn.to/31B1xmm3. Finn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446-2455. doi:10.1182/blood-2018-05-8504614. Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37(11):912-922. doi:10.1200/JCO.18.00915